ArticleJournal of the American Heart Association2015
Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice.
Article in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.Nature communications · 2020Trial
- Alogliptin repositioning confers protection against diclofenac-induced liver injury by inhibiting TLR4/NF-κB, ROS/TXNIP, and NLRP3 inflammasome-mediated pyroptosis in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Repositioning of Alogliptin to Mitigate Secondary Injury Induced by Repetitive TBI: Potential Role of its Antioxidant and Anti- Inflammatory Effects.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- Article
- Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis.Scientific reports · 2022Article
- DPP4 as a Potential Candidate in Cardiovascular Disease.Journal of inflammation research · 2022Review
- Hypertension in diabetes care: emerging roles of recent hypoglycemic agents.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Review
- DPP4 Activity, Hyperinsulinemia, and Atherosclerosis.The Journal of clinical endocrinology and metabolism · 2021Review
- Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways.The international journal of neuropsychopharmacology · 2021Article
- Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors.Cardiovascular diabetology · 2021Article
- Dipeptidyl peptidase-4 is increased in the abdominal aortic aneurysm vessel wall and is associated with aneurysm disease processes.PloS one · 2020Article
- miR-29b Mediates the Chronic Inflammatory Response in Radiotherapy-Induced Vascular Disease.JACC. Basic to translational science · 2019Article
- Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo.International journal of nanomedicine · 2019Article
- Molecular and clinical roles of incretin-based drugs in patients with heart failure.Heart failure reviews · 2018Review
- The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury.Molecular medicine reports · 2017Article
- The regulatory role of DPP4 in atherosclerotic disease.Cardiovascular diabetology · 2017Review
- New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.BioMed research international · 2017Review
- Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.Mediators of inflammation · 2016Review
- Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.Cardiovascular diabetology · 2015Review
- The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe results of recent studies suggest that dipeptidyl-peptidase-4 inhibitors have antiatherogenic effects. However, whether or not dipeptidyl-peptidase-4 inhibitors could suppress arterial inflammation and intimal hyperplasia after injury remains undetermined. The present study aims to clarify the anti-inflammatory effects of the dipeptidyl-peptidase-4 inhibitor, alogliptin (AGP), on the arteries of atherogenic low-density lipoprotein receptor-deficient (LKO) mice. METHODS AND
resultsWe compared intimal hyperplasia in LKO mice 2 weeks after femoral artery injury using an external vascular cuff model. All mice received oral injection of AGP (20 mg/kg per day) or normal saline (control) once daily for 14 days. Fasting blood sugar levels, serum cholesterol levels, or blood pressure did not significantly differ between the 2 groups. Plasma levels of active glucagon-like peptide-1 were higher in the AGP than in the control LKO mice (22.2±1.9 versus 15.6±0.9 pg/mL; P<0.05). Compared with saline, AGP significantly reduced intimal hyperplasia (1087±127 versus 1896±140 μm(2); P<0.001) as well as the intima/media ratio (0.08±0.01 versus 0.16±0.02; P<0.001). Immunostaining showed that AGP reduced proliferating cells (proliferating cell nuclear antigen-positive nuclei; P<0.001), percent smooth-muscle cell area (α-SMA-positive cells; P<0.001), inflammatory cells infiltration (lymphocyte antigen 6 complex-positive cells; P<0.05), tumor necrosis factor-α expression (P<0.05), and percent phospho-NF-κB-positive cell compared with saline. Levels of tumor necrosis factor -α (0.5-fold P<0.05), monocyte chemoattractant protein 1 (0.3-fold P<0.01), and interleukin-1β (0.2-fold P<0.05) mRNA were lower in the injured arteries of the AGP than in the control group.
conclusionsAGP appeared to suppress neointimal formation by inhibiting inflammation, independently of its effects on glucose or cholesterol metabolism in atherogenic LKO mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.